Tutti gli studi
ReclutamentoConferma terapeutica (Fase III)Interventistico

AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF MIGALASTAT HCL IN SUBJECTS WITH FABRY DISEASE AND AMENABLE GLA VARIANTS AND SEVERE RENAL IMPAIRMENT OR END-STAGE RENAL DISEASE TREATED WITH HEMODIALYSIS

Fabry disease is a rare inherited condition where fatty substances build up in the body, which can cause serious damage to organs like the kidneys. Galafold (migalastat) is an approved capsule treatment, but doctors need more information about how it works in people whose kidneys are severely damaged or who need regular haemodialysis. In this clinical trial, adults with Fabry disease and severe kidney problems will take Galafold capsules. The research team will track how the body breaks down and removes the drug by testing levels in the blood and urine. They will also keep a close watch on overall health through regular check-ups, heart scans, and blood tests. The aim is to find out if the medicine is safe, well-tolerated, and dosed correctly for people living with severe kidney disease.

A colpo d'occhio

Stato
Reclutamento
Fase
Conferma terapeutica (Fase III)
Sponsor
Amicus Therapeutics Inc.
Obiettivo di iscrizione
5
Inizio
19 Oct 2022

Di cosa tratta questo studio?

Fabry disease is a rare genetic condition caused by a missing or faulty enzyme in the body. Without enough of this enzyme, fatty substances slowly build up inside cells, leading to pain and potential damage to vital organs such as the heart and kidneys over time. Many people with Fabry disease eventually develop severe kidney problems and may require kidney dialysis to clean their blood.

Galafold (migalastat) is a treatment taken as a capsule by mouth. It works like a helper or 'chaperone', helping the body's own enzyme work more effectively. However, Galafold only works for people who have specific genetic changes (known as amenable variants). Because kidneys normally help filter medicines out of the body, having severe kidney disease can change how a drug builds up or clears away.

This study is important because it focuses specifically on people with Fabry disease who also have severe kidney impairment or end-stage kidney failure treated with haemodialysis. Researchers want to understand the best and safest dose for this group, ensuring that patients with advanced kidney disease are not left without treatment options.

Punti chiave

  • Testing Galafold (migalastat) capsules in adults with Fabry disease and severe kidney disease or dialysis.
  • Aims to find out how the medicine is cleared by the body and check its safety.
  • Open to men and women aged 18 and older with a confirmed responsive (amenable) gene variant.
  • Everyone in the study receives the active medicine; there is no dummy pill.
  • Participation includes close health monitoring, blood and urine tests, and heart checks.

Chi può essere idoneo?

This study is open to adults aged 18 and older who have been diagnosed with Fabry disease. Because Galafold only works on certain types of the condition, participants must have a genetic test showing they have an 'amenable' gene variant that responds to the medicine.

Participants must also have severe kidney problems or end-stage kidney disease that requires regular haemodialysis. Both men and women can take part.

The study team will review your full medical history, current treatments, and test results to decide if joining the study is safe and right for you.

Questo studio potrebbe fare al caso tuo?

Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.

  1. I am aged 18 or older.
  2. I have a confirmed diagnosis of Fabry disease.
  3. My genetic test shows an 'amenable' gene variant that can respond to Galafold.
  4. I have severe kidney disease or I receive regular haemodialysis for kidney failure.
  5. I am willing to attend regular hospital appointments for check-ups and blood tests.
Rispondi a ogni domanda per vedere il tuo risultato.

Cosa comporta la partecipazione?

If you take part, you will receive Galafold (123 mg) capsules to take as instructed by the study doctor. Because this is an 'open-label' study, you and your doctors will know that you are receiving the real medicine rather than a dummy pill (placebo).

You will need to attend regular clinic visits. During these visits, the medical team will take blood and urine samples to measure the amount of medicine in your body and check levels of a fatty marker linked to Fabry disease. If you are on haemodialysis, some tests will be timed around your dialysis sessions. The team will also monitor your overall health with physical examinations, blood pressure and pulse checks, and heart traces (ECGs). The study team will explain the exact schedule and total length of the trial before you decide to join.

Rischi e benefici potenziali

Taking part may help doctors understand how to treat Fabry disease in people with severe kidney disease, which could benefit you and future patients. You will also receive very close health monitoring from kidney and Fabry disease specialists. However, there are potential risks, including side effects from Galafold such as headaches, nausea, or dizziness. Regular blood tests and clinic appointments may also take up a significant amount of your time. Taking part is completely voluntary, and you can change your mind and leave the study at any point without it affecting your normal NHS care.

Luoghi (3)

Alcune posizioni dei siti sono approssimative. Stiamo migliorando questo — si prega di verificare con il team di prova prima di viaggiare.
  • —
    Non verificato
    Spagna
  • —
    Non verificato
    Francia
  • —
    Non verificato
    Portogallo

Domande comuni

What does an 'amenable' gene variant mean?

It means your specific genetic type of Fabry disease produces an enzyme that can respond to and be helped by Galafold. A genetic test can confirm this.

Will I receive a dummy pill (placebo)?

No. This is an open-label trial, which means all participants receive the active Galafold capsules.

Can I take part if I am already on dialysis?

Yes. The trial is specifically designed for people with severe kidney problems, including those receiving regular haemodialysis.

Will I have to pay to take part in this study?

No. The study medicine and all trial-related tests are provided free of charge, and travel expenses are often reimbursed.

What happens if I decide I want to stop?

You are free to leave the trial at any time. Your normal medical care and relationship with your doctors will not be affected in any way.

Come saperne di più

Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.

Interessato a partecipare?

Registrati per ricevere aggiornamenti

Condividi i tuoi dettagli e il team di ricerca per "AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND PHARMACOKINET…" ti contatterà se potresti essere idoneo. Parla sempre con il tuo medico prima di accettare di partecipare.

Discussione

Discussione della comunità

Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.